HOME >> MEDICINE >> NEWS
Medicare+Choice enrollees face continued cost increases in 2003, costs have doubled since 1999

en higher cost burdens. Those in poor health will spend about three times more out-of-pocket than those in good health. Costs for sicker plan enrollees also increased at a faster rate over the four-year period than did costs for healthy enrollees. From 1999 to 2003, average out-of-pocket costs for beneficiaries in poor health climbed from $2,211 to $5,305. Annual costs for those in good health rose from $836 to $1,564.

"Health insurance is designed to protect individuals from high health care costs that could inflict financial hardship," said Karen Davis, president of The Commonwealth Fund. "The steadily increasing financial burden on sicker beneficiaries is of notable concern."

Average Annual Out-of-Pocket Cost-Sharing for Medicare+Choice Enrollees, 19992003

    1999 - $976
    2000 - $1185
    2001 - $1438
    2002 - $1786
    2003 - $1964

Note: Results are weighted by plan enrollment. Out-of-pocket cost estimates include the Medicare Part B premium, the Medicare+Choice premium, spending for physician and hospital copayments, and outpatient prescription drugs not covered by the M+C package.

Source: Mathematica Policy Research analysis of Medicare Compare using HealthMetrix Research's Medicare HMO Cost Share Report Methodology.


'"/>

Contact: Mary Mahon
mm@cmwf.org
212-606-3853
Commonwealth Fund
11-Aug-2003


Page: 1 2

Related medicine news :

1. Trends in private Medicare+Choice plans provide warnings for Medicare debate
2. Medicare+Choice bills may stop exodus of plans, but are not likely to expand enrollment in HMOs
3. Survey: Medicare gets higher marks from enrollees than private insurance
4. Study finds continued reduction in breast cancer incidence associated with longer use of raloxifene
5. Anthrax survivors continued to have health problems one year after exposure
6. Roche pledges continued support for Organ Transplantation Research Foundation
7. Significantly lower physical activity levels in obese adolescents contribute to continued obesity
8. ICAAC highlight: MAC prophylaxis can be safely discontinued in HIV-infected patients who respond to HAART
9. Obesity among African-American stroke survivors increases risk factors for recurrent stroke
10. Even mild depression increases long-term mortality in heart failure
11. Hormone therapy increases risk of urinary incontinence

Post Your Comments:
(Date:5/18/2013)... 18, 2013 In a May 14, ... Double Mastectomy After Discovering Cancer Gene,” Fox News reported ... upon learning that she carried a gene that doctors ... cancer and a 50 percent risk of ovarian cancer ... on May 16, 2013 with a blog post entitled ...
(Date:5/18/2013)... (May 18, 2013) A ground-breaking advance in ... according to research presented today at Digestive Disease ... minimal withdrawal time for colonoscopies and exploring safer ... colonoscopy, doctors use a device called a colonoscope ... colorectal cancer allows a doctor to look for ...
(Date:5/18/2013)... York, New York (PRWEB) May 18, 2013 ... Gynecare pelvic mesh products continue to move forward in ... Superior Court, Bernstein Liebhard LLP reports. According to a ... Conference in the Ethicon pelvic mesh litigation will be ... that 2,755 complaints have been filed in the proceeding ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- It ... but new research shows that college women are more likely ... than are college men. Much of this difference ... on a weekly basis is much lower for women than ... for men. But, there,s good reason for that difference. Women ...
(Date:5/18/2013)... May 18, 2013 After working diligently for ... SizeItUp formally announced the integration of the fitment specs ... Genesis is set to stun the automobile market with its ... Hyundai Genesis is marked as the latest entry in the ... vehicles lined up for the year 2013. , Aptly ...
Breaking Medicine News(10 mins):Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
(Date:5/17/2013)... Mass. , May 17, 2013  Boston Scientific ... participate at the annual EuroPCR Scientific Program May 21-24 ... are pleased to present a particularly rich and diversified ... Keith Dawkins , M.D., global chief medical ... trials will be presented, including the NG PROMUS trial, ...
(Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
Cached News: